Member Login
  1. Stocks
    2. /
  2. Zymeworks Inc. (NYSE: ZYME)
    3. /

NYSE:ZYME (Zymeworks Inc.)

About ZYME

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its lead clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
Financial Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

    • Zymeworks Inc. (NYSE: ZYME) Latest News

    Investing

    3 Hot Stocks to Buy in October

    | Ambrose O'Callaghan

    Markets are reeling, but investors should still look to add stocks like Zymeworks Inc (TSX:ZYME)(NYSE:ZYME) right now.

    Read more »

    Tech Stocks

    These Were the Worst-Performing Stocks on the TSX Last Week

    | Ryan Vanzo

    Markets keep rising, but there are bargains to be had. Learn more about beaten-down stocks like Imperial Metals Corp (TSX:III),…

    Read more »

    Investing

    3 Top TSX Stocks for the Future

    | Ambrose O'Callaghan

    Investors gearing up for the future should target stocks like Zymeworks Inc. (TSX:ZYME)(NYSE:ZYME) and others.

    Read more »

    Stocks for Beginners

    3 Top Canadian Pharma Stocks for Ambitious Investors

    | Victoria Hetherington

    Pharma stocks like Zymeworks Inc. (TSX:ZYME)(NYSE:ZYME) are coming into their own, offering growth investors a lot of upside potential.

    Read more »

    Top TSX Stocks

    3 BioPharm Stocks Yielding 100% Yearly Returns

    | Debra Ray

    Zymeworks Inc. (TSX:ZYME)(NYSE:ZYME), among other Canadian biopharmaceutical companies, has been hit with shorter supplies and rising demand.

    Read more »

    Dividend Stocks

    3 Top Canadian Healthcare Stocks for Growth Investors

    | Victoria Hetherington

    Zymeworks Inc. (TSX:ZYME)(NYSE:ZYME) and two other healthcare stocks may have flown under the radar of recession-proofing investors.

    Read more »

    Investing

    This 2017 IPO Still Boasts Massive Growth Potential

    | Ambrose O'Callaghan

    Zymeworks Inc. (TSX:ZYME)(NYSE:ZYME) stock has nearly doubled from its IPO price in 2017, and the biotech’s product candidates should really…

    Read more »

    Investing

    Alert! 2 High-Growth Stocks to Buy Before 2020

    | Ambrose O'Callaghan

    Zymeworks Inc. (TSX:ZYME)(NYSE:ZYME) and Stars Group Inc. (TSX:TSGI)(NASDAQ:TSG) are well-positioned to benefit from big growth in their respective markets.

    Read more »

    Investing

    Top 2 TSX Healthcare Stocks to Buy in June

    | Ambrose O'Callaghan

    Zymeworks Inc. (TSX:ZYME)(NYSE:ZYME) and BELLUS Health Inc. (TSX:BLU) offer huge potential in the burgeoning healthcare sector.

    Read more »

    Investing

    This High-Growth Biopharma Stock Just Got Some Great News

    | Ambrose O'Callaghan

    Zymeworks Inc. (TSX:ZYME)(NYSE:ZYME) just saw a top product candidate hit a milestone. This is a growth stock to hold onto…

    Read more »

    Cannabis Stocks

    2 High-Growth Stocks That Could Explode in the Next Decade

    | Ambrose O'Callaghan

    Stocks like Aurora Cannabis Inc. (TSX:ACB)(NYSE:ACB) and Zymeworks Inc. (TSX:ZYME)(NYSE:ZYME) offer massive growth potential to investors with a long time…

    Read more »

    Investing

    2 Stocks That Can Make You a TFSA Millionaire

    | Ambrose O'Callaghan

    Aspiring TFSA millionaires should target biotech stocks like Fennec Pharmaceuticals Inc. (TSX:FRX)(NASDAQ:FENC) and Zymeworks Inc. (TSX:ZYME)(NYSE:ZYME) in 2019.

    Read more »